ASCO 2023 | Using metronomic chemotherapy as a second-line treatment in head and neck cancer

Rushabh Kiran Kothari, MD, Narayana Multispeciality Hospital, Ahmedabad, India, explains that in low and middle income countries, access to immunotherapeutic agents is challenging. Metronomic chemotherapy can become a standard of care for second line treatment in these regions in most settings. In higher income countries, where access is greater, many patients are receiving immunotherapeutic agents as first-line therapy. Therefore, second-line options need to be explored. In this setting, metronomic chemotherapy could be administered in second-line, post exposure to first-line immunotherapy and chemotherapy. A caveat is the higher rates of oropharyngeal carcinoma in higher income countries, however in clinical practice, this regiment has been shown to work well even in this scenario. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.